BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-matched related donors (RDs) and allogeneic HCT using HLA-matched unrelated donors (URDs) produce similar outcomes for patients with acute myelogenous leukemia, whereas the donor source has been reported to be a predictor of outcomes in myelodysplastic syndrome. METHODS: Post-HCT outcomes for 1458 acute lymphoblastic leukemia patients from 2000 to 2011 were analyzed, and RD and URD transplants were compared. RESULTS: The median age was 37 years (range, 18-69 years). In the multivariate analysis, HLA 8/8 allele-matched URD recipients had similar transplant-related mortality (TRM) and all-cause mortality in comparison with RD recipients (hazard ratios [HRs] 
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is a potentially lifesaving treatment for patients suffering from acute leukemia, lymphoma, and other hematologic diseases. Siblings with matching human leukocyte antigen (HLA) are the preferred donor source, but only approximately one-third of patients have an HLA-matched related donor (RD). If an RD is not available, a matched unrelated donor (URD) is sought. Depending on the recipient's race and ethnicity, the likelihood of finding a fully HLA allele-matched (HLA-A, HLA-B, HLA-C, and HLA-DRB1 [8/8] ) URD ranges from 16% to 75%, and the likelihood ranges from 66% to 97% for a 7/8 HLA match. [1] [2] [3] [4] [5] HCT using a URD has been associated historically with a higher incidence of graft failure, more graft-versus-host disease (GVHD), and lower survival in comparison with RD transplants. 6 However, more recent data have shown that survival rates for URD HCT have improved significantly, with 2-year survival rates for URD recipients with acute lymphoblastic leukemia (ALL) rising from 23% in 1987-1998 to 40% in [2003] [2004] [2005] [2006] . 1, 7 A recent analysis comparing the outcomes after RD, 8/8 URD, and 7/8 URD HCT for acute myelogenous leukemia (AML) patients demonstrated that 8/8 URD HCT recipients had survival rates similar to those of RD HCT recipients, whereas 7/8 URD recipients had higher early mortality; this suggests that contemporary use of URD and RD HCT produces similar survival outcomes for AML patients. 8 A subsequent study examined the same question among patients with myelodysplastic syndrome, but in contrast to the findings for AML, the donor source was an important predictor of outcomes. 9 Recipients of 7/8 URD HCT had worse 3-year survival than RD and 8/8 URD groups. 9 Although AML patients had lower relapse risks with 7/8 URD transplants versus RD transplants (hazard ratio [HR] , 0.78 [95% confidence interval (CI), 0.63-0.98]), 8 this relation was not seen in myelodysplastic syndrome (HR, 1.02 [95% CI, 0.66-1.60]), 9 and this indicates that there may exist a diseasespecific component to the graft-versus-leukemia (GVL) effect. Evaluating the role of the donor source in determining the outcomes of HCT for specific diseases might clarify the potency of the GVL effect. We investigated the outcomes of RD, 8/8 URD, and 7/8 URD HCT for patients with ALL. Furthermore, we sought to evaluate whether the donor source impact on outcomes differs with the conditioning regimen intensity because patients undergoing reduced-intensity conditioning HCT rely more on the GVL effect of their transplant to prevent disease relapse. 10 
MATERIALS AND METHODS

Data Source
The Center for International Blood and Marrow Transplant Research (CIBMTR) is a combined research program of the Medical College of Wisconsin and the National Marrow Donor Program. The CIBMTR comprises a voluntary network of more than 450 transplantation centers worldwide that contribute detailed data on consecutive allogeneic and autologous HCT to a centralized statistical center. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. Protected health information used in the performance of such research is collected and maintained by the CIBMTR in its capacity as a public health authority under the Health Insurance Portability and Accountability Act privacy rule. Additional details regarding the data source are described elsewhere.
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Patient Selection
The patient population consisted of adult patients (18 years) with B-lineage ALL undergoing their first allogeneic HCT in the United States between 2000 and 2011 who had comprehensive data reported to the CIBMTR. A total of 1458 cases fulfilling the inclusion criteria were identified. Of these, 440 received RD transplants from matched siblings, 729 received 8/8 HLA-matched URD transplants, and 289 received 7/8 HLA-matched URD transplants. Patients undergoing umbilical cord blood transplantation and patients receiving stem cells from identical twins or HLA-mismatched, haploidentical, or non-sibling-related donors were excluded. Patients whose disease status at transplant was missing were excluded, and the pre-HCT presence or absence of minimal residual disease was not assessed. Patients whose grafts were depleted of T cells ex vivo or who underwent CD34 cell selection were excluded. Patients receiving post-HCT cyclophosphamide for GVHD prophylaxis were also excluded. The population was limited to patients with B-cell lineage disease only.
Study Endpoints and Definitions
The primary outcome studied was survival. Patients were considered to have an event at the time of death from any cause; survivors were censored at the time of last contact. Leukemia-free survival (LFS) was defined as the time from transplantation to treatment failure (death or relapse). Relapse was defined as leukemia recurrence defined with hematologic criteria as reported by the centers to the CIBMTR, and transplant-related mortality (TRM) was considered a competing event. TRM was defined as death in remission, and relapse was considered a competing event. Acute GVHD was graded according to consensus criteria. 12 Chronic GVHD was diagnosed with standard criteria. 13 For the cumulative incidence of GVHD, death without GVHD was considered a competing event.
Statistical Analysis
Overall survival (OS) and LFS estimates for RD, 8/ 8 URD, and 7/8 URD recipients were calculated on the basis of Kaplan-Meier estimates, and the 95% CIs were calculated with the variance derived from Greenwood's formula. The cumulative incidence for TRM for the 3 groups was calculated with disease relapse as the competing risk, and the cumulative incidence for relapse was calculated with TRM as the competing risk. Similarly, death was a competing risk for the cumulative incidence of acute and chronic GVHD.
14 The Kruskal-Wallis test for continuous covariates and Fisher's exact test for proportions were used to compare patient-, disease-, and transplantrelated characteristics between groups. Log-rank tests were used to compare OS and LFS between RD, 8/ 8 URD, and 7/8 URD recipients. Similarly, unadjusted comparisons of the 3 groups of patients in terms of treatment-related mortality and relapse were performed via Gray's test for cumulative incidence curves. All P values were 2-sided.
The Cox proportional hazards regression model was used to compare 8/8 URDs, 7/8 URDs, and RDs in terms of OS, LFS, TRM, relapse, acute GVHD, and chronic GVHD after adjustments for other risk factors. Patientrelated variables (age at diagnosis, sex, Karnofsky performance score [KPS] , and race), disease-related variables (white blood cell count at diagnosis, cytogenetics, tyrosine kinase inhibitor usage at any time before transplantation, disease status at transplant, time to achieve first complete remission [CR1] for patients undergoing transplantation during CR1, and duration of CR1 for patients undergoing transplantation during their second complete remission [CR2]), and transplant-related variables (donor age, donor-recipient sex matching, recipient cytomegalovirus status, conditioning regimen intensity, graft source, year of HCT, GVHD prophylaxis regimen, and use of anti-thymocyte globulin) were included in multivariate analyses using the Cox proportional hazards regression with a stepwise variable selection technique; P .05 was the criterion for inclusion in the final models. Optimal cut points for continuous covariates were determined by maximization of the overall mortality HR. The main factor being tested in this study was the effect of the donor source (8/8 URD vs 7/8 URD vs RD) on clinical endpoints; therefore, this variable was included in all models. The proportional hazards assumption was examined for each variable, and if it was violated, variables were included as time-dependent covariates. The interaction between the main effect and significant covariates was tested; no significant interactions were found. A multivariate analysis was also performed after the study population was restricted to patients undergoing transplantation during CR1 and CR2 or CR1 alone.
RESULTS
Patients
Baseline population characteristics for patients with B-cell ALL are summarized in Table 1 . The median follow-up times were 46, 61, and 72 months for RD, 8/8 URD, and 7/8 URD recipients, respectively. Patients in the URD group were younger than the RD patients. The median age for the entire cohort was 37 years (range, 18-69 years). KPSs were similar across all 3 groups. Across the 3 groups, patients were most commonly white, with the 8/8 URD group having a higher proportion of white patients. The white blood cell count at diagnosis was similar across all 3 groups. Among patients with Philadelphia chromosome ALL, the RD group had a greater percentage receiving a tyrosine kinase inhibitor as part of their treatment. RD recipients were more likely to undergo transplantation during CR1 in comparison with the URD groups, which had a higher percentage undergoing transplantation during CR2. The time from diagnosis to achieving CR1 for all patients who achieved CR1 and the duration of CR1 for patients undergoing transplantation during CR2 were similar across all groups. The conditioning regimen intensity and the GVHD prophylaxis regimens were similar across all 3 groups. The use of in vivo T-cell depletion (anti-thymocyte globulin and/or alemtuzumab) was more common in the URD groups. RD recipients received their transplants more recently than the URD groups and were more likely to have received peripheral blood stem cells (PBSCs). (Table 2) . Covariates with adverse effects on OS included the following: age > 52 years, low KPS, nonwhite race, a poor cytogenetic profile (Philadelphia chromosome-negative), use of cyclosporine A (CSA), transplantation during CR1 for patients who took longer than 4 weeks to achieve complete remission, transplantation during CR2 with a short duration of CR1, and advanced disease status at transplant. The use of PBSCs was also associated with a higher risk of mortality; however, this risk became apparent only 2 years after transplantation. There was no significant difference in OS when we compared myeloablative conditioning (MAC) with or without total body irradiation (TBI) and reduced-intensity/nonmyeloablative conditioning (Supporting Table 1 [see online supporting information]). The 5-year probability of OS, adjusted for other significant variables, was 35% (95% CI, 30%-40%), 36% (95% CI, 32%-40%), and 28% (95% CI, 22%-33%) for RD, 8/8 URD, and 7/8 URD recipients, respectively (Table 3 and Fig. 1 Table 2 ). Adverse covariates for TRM were as follows: recipient age > 52 years, low KPS, nonwhite race, CSA use, and PBSC use. PBSC use was associated with higher rates of TRM, but this started only 2 years after HCT. Reducedintensity/nonmyeloablative conditioning regimens were associated with a decreased risk of TRM. The 5-year cumulative incidence of TRM, adjusted for other significant variables, was 27% (95% CI, 22%-31%), 32% (95% CI, 28%-36%), and 45% (95% CI, 38%-52%) for RD, 8/8 URD, and 7/8 URD recipients, respectively (Table 3) .
Original Article Table 2 ). Adverse covariates for relapse included the following: low KPS, nonwhite race, poor cytogenetic profile (Philadelphia chromosome-negative), conditioning regimen lacking TBI, reduced-intensity/nonmyeloablative conditioning, transplantation during CR2 with a short CR1 duration, and advanced disease status at transplant. The adjusted 5-year cumulative incidence of relapse was 43% (95% CI, 38%-48%), 33% (95% CI, 29%-37%), and 31% (95% CI, 25%-36%) for RD, 8/8 URD, and 7/ 8 URD recipients, respectively (Table 3) .
LFS
There was no increased risk of treatment failure, defined as death or relapse (the inverse of LFS), associated with The 5-year probability of LFS, adjusted for other significant variables, was 32% (95% CI, 27%-36%), 34% (95% CI, 30%-38%), and 25% (95% CI, 20%-30%) for RD, 8/8 URD, and 7/8 URD recipients, respectively (Table 3 and Fig. 2 Table 2 ). A subgroup analysis of outcomes restricted to patients receiving HCT during CR1 (n 5 756) was performed, and this yielded results largely similar to the results seen in the overall cohort (Supporting Table 2 [see online supporting information]). An additional subgroup analysis restricted to patients receiving HCT during either CR1 or CR2 was also performed, and this yielded the same results found for the entire study population (data not shown).
Causes of death
DISCUSSION
For adult patients with ALL, allogeneic HCT from an RD or URD has been shown to be a potentially curative, lifesaving treatment. [1] [2] [3] [4] [5] [6] We suspect a possible relation between relapse and TRM that is dependent on disease because each disease carries its own unique population of patients varying in its median age, comorbidities, ability to tolerate GVHD, and so forth. Although a particular donor source may have high relapse rates and low TRM for one disease, these outcomes may differ for other diseases. We, therefore, evaluated the impact of the donor source on allogeneic HCT outcomes in the setting of Bcell ALL.
Studies have looked at HCT outcomes among ALL patients as they relate to the donor source and have shown similar outcomes for RD and URD transplants; however, their patient populations have been limited in size. 15, 16 We focused on a larger, more recent cohort of ALL patients with high-resolution HLA matching performed for donors, which has contributed to better outcomes for hematopoietic stem cell transplantation. 17 Our results show no significant difference between RD and 8/8 URD Abbreviations: CI, confidence interval; HR, hazard ratio; GVHD, graft-versus-host disease; LFS, leukemia-free survival; OS, overall survival; RD, related donor; TRM, transplant-related mortality; URD, unrelated donor. The significant covariates in each of the final models were as follows: use of anti-thymocyte globulin/alemtuzumab, donor/recipient sex matching, GVHD prophylaxis, and graft type for GVHD; Karnofsky performance score, race, cytogenetics, conditioning regimen, and disease status at transplant for relapse; age, Karnofsky performance score, race, GVHD prophylaxis, graft type, and conditioning regimen for TRM; age, Karnofsky performance score, race, cytogenetics, GVHD prophylaxis, disease status at transplant, and year of transplant for LFS; and age, Karnofsky performance score, race, cytogenetics, GVHD prophylaxis, disease status at transplant, and graft type for OS. recipients in OS, LFS, or TRM. In contrast, 7/8 URD recipients had a greater incidence of adverse outcomes, with the multivariate model showing an increased risk of death from any cause and TRM. Recipients of 7/8 URD HCT had worse LFS than RD and 8/8 URD recipients; however, this difference reached statistical significance only in comparison with 8/8 URD recipients. We hypothesize that the 7/8 URD group's lower relapse rates account for the similarity in LFS in comparison with RD transplants. However, the 7/8 URD group's higher mortality risk can be attributed to the excessive TRM associated with this donor source. Others have shown a mismatched URD source to have a negative impact on survival; however, these studies have been limited by a small sample size or by the restriction of their patient population to Philadelphia chromosome-negative patients undergoing transplantation during their first remission. 18, 19 We have confirmed these findings and have done so over a broad spectrum of ALL patients.
Tomblyn et al 15 previously found similar outcomes when they compared RDs with matched and partially matched URDs; however, their patient population was limited in size (matched URDs, n 5 19; partially matched URD, n 5 23), and they also focused on an overall younger population. Our study found that a recipient age > 52 years was associated with significantly worse OS in comparison with a younger age. Because they also found recipient age to have an impact on outcomes, their study's overall younger population may account for some of the similarities in outcomes between RDs and URDs. The authors postulated that for patients undergoing transplantation during CR2, perhaps a longer duration of CR1 represented a prognostic indicator for a risk of adverse outcomes, and our study has shown this to be true; OS, LFS, and relapse were all negatively affected when patients underwent transplantation during CR2 with a CR1 duration 30 months. Furthermore, when we restricted our population only to patients undergoing transplantation during CR1, we found the results similar to those for the entire study population. Another aspect of HCT that we aimed to address in this study was whether the GVL effect plays a role in outcomes. Patients undergoing reduced-intensity conditioning HCT rely more on the GVL effect of their transplant to prevent disease relapse. 10 Reduced-intensity conditioning combined with an RD transplant has been shown to be a viable option for those not eligible for MAC; however, the conditioning regimen intensity was addressed only for RD transplants without any comparison with URDs. 20 Marks et al 21 directly compared conditioning regimens in adults with Philadelphia chromosome-negative ALL receiving RD or URD transplants after undergoing full-intensity or reduced-intensity conditioning, and they found similar OS, LFS, and relapse rates regardless of the conditioning intensity. We have also shown there to be no difference in OS or LFS when MAC with TBI, MAC without TBI, and reduced-intensity conditioning are compared across all donor sources; however, because of the small sample size for those receiving chemotherapybased MAC (n 5 164), the statistical power to detect a difference is limited. Our multivariate analysis has shown that URD recipients have a lower relapse risk than RD recipients. The development of chronic GVHD has been previously associated with decreased relapse rates. 22 Mohty et al 20 demonstrated that patients who received a reduced-intensity conditioning regimen and subsequently developed chronic GVHD had greater OS than those without chronic GVHD. In our analysis, the URD groups had a greater risk of chronic GVHD, and this may account for the decreased risk of relapse in these groups. Although the URD groups had less risk of relapse, they did not benefit from improved LFS, likely because of the higher incidence of acute and chronic GVHD and subsequently higher rates of TRM. Although URD recipients did suffer less frequent relapse, the incidence in all 3 groups remained excessive, and further investigation should be made into strategies to reduce this incidence.
In addition, although the Philadelphia chromosome has traditionally been considered a prognostic factor for adverse outcomes, 23, 24 Postow et al 25 found that it may not be an adverse factor in contemporary practice. Our results showed that the presence of the Philadelphia chromosome did not have a negative impact on any outcomes, although Philadelphia chromosome-negative patients had a greater risk of relapse in comparison with Philadelphia chromosome-positive patients. We speculate that this is due to increased use of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive ALL.
Historically, peripheral blood and bone marrow transplants have been shown to have similar survival outcomes for both RD and URD recipients with a wide array of hematologic malignancies, although peripheral blood has been associated with a greater incidence of chronic GVHD. 26, 27 Our study confirmed a peripheral blood transplant to be a risk factor for chronic GVHD as well as acute GVHD. Furthermore, at > 24 months after HCT, peripheral blood was associated with a greater risk of TRM and all-cause mortality. The initial results of Blood and Marrow Transplant Clinical Trials Network trial 0201, a prospective trial comparing outcomes with bone marrow and PBSC transplants, have shown similar OS, disease-free survival, and TRM between graft types, higher rates of chronic GVHD in PBSC recipients, and superior 5-year psychological well-being and quality-oflife scores for bone marrow recipients. 27, 28 Given these results as well as our own findings, we recommend using bone marrow grafts whenever possible.
In summary, our study confirms that in the absence of an RD, the use of an 8/8 URD yields similar survival, whereas a 7/8 URD is associated with inferior survival. An 8/8 URD is associated with a 30% higher probability of chronic GVHD in comparison with an RD. Therefore, despite similar survival with 8/8 URDs and RDs, we conclude that RDs remain the gold standard. HCT from an 8/8 URD should be considered a reasonable alternative when an 8/8 URD is the only available donor.
Future studies comparing haploidentical and 7/ 8 URD transplants will be critical for determining the optimal alternative donor type when a matched donor cannot be identified. These results should inform clinicians, patients, and researchers in their design of prospective clinical trials.
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